BLAINJECTIONINJECTABLE
Approved
Sep 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
2/8 — Basic
AUKELSO (denosumab-kyqq) by Biocon is rank ligand blocking activity [moa]. First approved in 2025.
Drug data last refreshed 15h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AUKELSO (denosumab-kyqq) is a monoclonal antibody biosimilar that blocks RANK ligand, a key regulator of bone resorption. This RANK ligand inhibitor is administered by injection and is used to treat patients with bone loss conditions. The drug works by preventing osteoclast activation, thereby reducing bone turnover and strengthening skeletal integrity.
Launch
Early-stage launch of a biosimilar in a mature market creates opportunities for brand builders and field teams to establish market position amid moderate competitive pressure.
Mechanism of Action
RANK Ligand Blocking Activity
Pharmacologic Class:
RANK Ligand Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on AUKELSO offers pharma professionals an opportunity to participate in a biosimilar launch with moderate competitive intensity and early-stage market capture challenges. This role suits professionals skilled in payer negotiation, rapid market penetration, and biosimilar-specific value proposition development.
Brand Manager
Worked on AUKELSO at Biocon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.